Shore Capital Reaffirms Buy Rating for Verona Pharma (VRP)

Verona Pharma (LON:VRP)‘s stock had its “buy” rating restated by research analysts at Shore Capital in a report released on Tuesday.

Shares of LON:VRP opened at GBX 119 ($1.54) on Tuesday. Verona Pharma has a 52-week low of GBX 100 ($1.29) and a 52-week high of GBX 189 ($2.45).

Verona Pharma (LON:VRP) last released its quarterly earnings results on Tuesday, May 8th. The company reported GBX (14.50) (($0.19)) earnings per share for the quarter, beating analysts’ consensus estimates of GBX (23.70) (($0.31)) by GBX 9.20 ($0.12).

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

See Also: Understanding Relative Strength Index

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply